# US 2003/0082178 A1 · Method and composition for altering a B cell mediated pathology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0082178 A1
- Document ID: US20030082178A1
- Status: Published application
- Kind: A1
- Application number: 09/927,121
- Filed: 2001-08-10
- Published: 2003-05-01
- Earliest claimed: 2000-08-11
- Assignees: Favrille, Inc.
- Inventors: Daniel P. Gold; Robert J. Shopes
- Web page: https://patentgrep.com/patent/US20030082178A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/195: {Chemokines, e.g. RANTES}
- A61K 39/39541: {against normal tissues, cells}
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for altering a B cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding VH and/or VL regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH). Since the conjugates comprise chimeric proteins made specifically from particular B cells from a patient having B cell mediated pathology, when it is administered to such a patient, with or without a cytokine, such as granulocyte-macrophage-CSF, or a chemokine, it can induce immune responses to alter such a B cell mediated pathology.

## Claims

### Claim 1

A method for altering a B cell mediated pathology in a patient, said method comprising:
administering a composition comprising a chimeric protein;
said chimeric protein comprising at least a portion of a VH or VL region and at least a portion of an immunoglobulin constant region;
wherein said VH or VL region is associated with a B cell clone from said patient having said B cell mediated pathology;
and said administering of said composition alters said B cell mediated pathology in said patient.

### Claim 2 (depends on 1)

The method of claim 1 wherein said composition further comprises a second chimeric protein that comprises at least a portion of VH or VL region and at least a portion of a second immunoglobulin constant region.

### Claim 3 (depends on 1)

The method of claim 1 wherein said immunoglobulin constant region comprises a human IgGγ1 constant region.

### Claim 4 (depends on 1)

The method of claim 1 wherein said VH or VL region is a VH region.

### Claim 5 (depends on 1)

The method of claim 1 wherein said VH or VL region is a VL region.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2 wherein said VH or VL region of said first chimeric protein comprises a VH region and said second chimeric protein comprises a VL region.

### Claim 7 (depends on 2)

The method of claim 2 wherein said second immunoglobulin constant region comprises a human κ or λ constant region.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2 wherein said VH or VL region is an entire variable region.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2 wherein said VL region is an entire variable region.

### Claim 10 (depends on 1, 2)

The method of claim 1 or 2 wherein said first or second immunoglobulin constant region is selected from the group consisting of a human IgGγ1 constant region, a human IgGγ2 constant region, a human IgGγ3 constant region, a human IgGγ4 constant region, a human IgA1 constant region, a human IgA2 constant region, a human IgM constant region, a human IgD constant region, a human IgE constant region, a human κ chain constant region, and a human λ chain constant region.

### Claim 11 (depends on 1)

The method of claim 1 wherein said chimeric protein is produced by a method comprising:
isolating a gene encoding at least a portion of a VH or VL region from B cells of said patient having said B cell mediated pathology;
inserting said gene encoding said VH or VL region and a gene encoding at least a portion of said immunoglobulin constant region into an expression vector to allow the expression of said first chimeric protein;
producing said chimeric protein by introducing said expression vector into insect cell lines; and
isolating said chimeric protein.

### Claim 12 (depends on 11)

The method of claim 11 further comprising the step of inserting a gene encoding at least a portion of a VH or VL region and a gene encoding at least a portion of a second immunoglobulin constant region into said expression vector to allow the expression of said second chimeric protein.

### Claim 13 (depends on 11, 12)

The method of claim 11 or 12 further comprises a step of conjugating said chimeric protein to a carrier protein.

### Claim 14 (depends on 13)

The method of claim 13 wherein said carrier protein is keyhole-limpet hemocyanin (KLH).

### Claim 15 (depends on 1)

The method of claim 1 wherein said composition is further co-administered with a cytokine or chemokine.

### Claim 16 (depends on 15)

The method of claim 15 wherein said cytokine is granulocyte-macrophage-colony stimulating factor (GM-CSF).

### Claim 17 (depends on 15)

The method of claim 15 wherein said chemokine is monocyte chemotactic protein 3 (MCR 3).

### Claim 18 (depends on 11)

The method of claim 11 wherein said expression vector is a baculovirus expression vector.

### Claim 19 (depends on 18)

The method of claim 18 wherein said baculovirus expression vector comprises a honey bee melittin secretory signal sequence and a human placental alkaline phosphatase secretory signal sequence.

### Claim 20 (depends on 19)

The method of claim 19 wherein said baculovirus expression vector further comprises a baculovirus AcNPV p10 promotor and AcNPV polyhedrin promotor, wherein said p10 promotor controls a honey bee melittin secretory signal sequence, and wherein said polyhedrin promotor controls a human placental alkaline phosphatase secretory signal sequence.

### Claim 21 (depends on 20)

The method of claim 20 wherein a gene encoding a chimeric protein comprising a VH region and a first immunoglobulin constant region is controlled by said p10 promotor in said baculovirus expression vector, a gene encoding a chimeric protein comprising a VL region and a second first immunoglobulin constant region is controlled by polyhedrin promotor in said baculovirus expression vector.

### Claim 22 (depends on 20)

The method of claim 20 wherein said gene comprising said VH or VL region and said gene encoding said immunoglobulin constant region is controlled by either said p10 promotor or polyhedrin promotor in said baculovirus expression vector.

### Claim 23 (depends on 11)

The method of claim 11 wherein said gene encoding said immunoglobulin constant region is a human IgGγ1 gene.

### Claim 24 (depends on 12)

The method of claim 12 wherein said gene encoding said second immunoglobulin constant region is a gene encoding for a human κ or λ constant region.

### Claim 25 (depends on 11, 12)

The method of claim 11 or 12 wherein said gene encoding said immunoglobulin constant region is selected from the group consisting of a human IgGγ1 constant region, a human IgGγ2 constant region, a human IgGγ3 constant region, a human IgGγ4 constant region, a human IgA1 constant region, a IgA2 human constant region, a human IgM constant region, a human IgD constant region, a human IgE constant region, a human κ chain constant region, and a human λ chain constant region.

### Claim 26 (depends on 11)

The method of claim 11 wherein said chimeric protein is selected from the group consisting of a protein comprising said VH region and a human IgGγ1 constant region; a protein comprising said VL region and a human κ chain constant region; and a protein comprising said VL region and a human λ chain constant region.

### Claim 27 (depends on 12)

The method of claim 12 wherein said first and second chimeric proteins comprise a protein comprising said VH region and a human IgGγ1 constant region and a protein comprising said VL region and a human κ or λ chain constant region.

### Claim 28 (depends on 11)

The method of claim 11 wherein said insect cell lines are Trichoplusia ni (Hi-5) or Spodoptera frugiperda (sf9) cell lines.

### Claim 29 (depends on 11, 12)

The method of claim 11 or 12 wherein said chimeric proteins are analyzed for expression by ELISA.

### Claim 30 (depends on 11, 12)

The method of claim 11 or 12 wherein said chimeric proteins are isolated using a protein selected from the group consisting of protein A, protein G, protein L and other proteins being able to bind to an immunoglobulin binding domain.

### Claim 31 (depends on 30)

The method of claim 30 wherein said other protein able to bind an immunoglobulin binding domain is an anti-immunoglobulin antibody.

### Claim 32 (depends on 1)

The method of claim 1 wherein said B cell mediated pathology is a B cell lymphoma.

### Claim 33 (depends on 32)

The method of claim 32 wherein said B cell lymphoma is refractory low grade lymphoma or follicular B cell lymphoma.

### Claim 34

A composition for altering a B cell mediated pathology in a patient comprising:
a chimeric protein that comprises at least a portion of a VH or VL region linked to at least a portion of an immunoglobulin constant region, wherein said VH or VL region is associated with a B cell clone from said patient having said B cell mediated pathology.

### Claim 35 (depends on 34)

A composition of claim 34 further comprising a second chimeric protein that comprises at least a portion of a variable region of a VH or VL region and at least a portion of a second immunoglobulin constant region, wherein said variable region is associated with a B cell clone from said patient having said B cell mediated pathology.

### Claim 36 (depends on 13, 14, 34, 35)

The composition of claim 34 or 35 wherein said chimeric proteins are produced in according to claim 13 or 14.

### Claim 37 (depends on 34, 35)

The composition of claim 34 or 35 wherein said immunoglobulin constant regions are selected from the group consisting of a human IgGγ1 constant region, a human IgGγ2 constant region, a human IgGγ3 constant region, a human IgGγ4 constant region, a human IgA1 constant region, a human IgA2 constant region, a human IgM constant region, a human IgD constant region, a human IgE constant region, a human κ chain constant region, and a human λ chain constant region.

### Claim 38 (depends on 34)

The composition of claim 34 wherein said immunoglobulin constant region is a human IgGγ1 constant region operatively linked to said VH region.

### Claim 39 (depends on 34)

The composition of claim 34 wherein said immunoglobulin constant region is a human κ or λ constant region operatively linked to said VL region.

### Claim 40 (depends on 35)

The composition claim 35 wherein said first and second chimeric proteins are said VH region operatively linked to a human IgGγ1 constant region and said VL region operatively linked to a human κ or λ constant region.

### Claim 41 (depends on 34, 35)

The composition of claim 34 or 35 further comprises a carrier protein.

### Claim 42 (depends on 41)

The composition of claim 41 wherein said carrier protein is keyhole-limpet hemocyanin (KLH).

### Claim 43 (depends on 34, 35)

The composition of claim 34 or 35 is further co-administered with a cytokine or chemokine.

### Claim 44 (depends on 43)

The composition of claim 43 wherein said cytokine is granulocyte-macrophage-CSF.

### Claim 45 (depends on 43)

The composition of claim 43 wherein said chemokine is a monocyte chemotactic protein 3 (MCP 3).

### Claim 46 (depends on 34, 35)

The composition of claim 34 or 35 wherein said composition is a vaccine.

### Claim 47 (depends on 34)

The composition of claim 34 wherein said B cell mediated pathology is a B cell lymphoma.

### Claim 48 (depends on 47)

The composition of claim 47 wherein said B cell lymphoma is non-Hodgkins lymphoma.

### Claim 49 (depends on 47)

The composition of claim 47 wherein said B cell lymphoma is refractory low grade or follicular B cell lymphoma.

### Claim 50 (depends on 34)

The composition of claim 34 is further administered by injection, inhalation, oral or transdermal delivery.

### Claim 51 (depends on 34)

The composition of claim 34 wherein said B cell mediated pathology is an autoimmune disease selected from the group consisting of multiple sclerosis, systemic lupus erythematosus, anti-Hu associated paraneoplastic neurological syndrome, autoimmune hepatitis, Type I diabetes, autoimmune thyroiditis, and scleroderma.

### Claim 52

An expression vector comprising (a) a chimeric gene encoding a portion of a VL region and a portion of a gene encoding a κ light chain, both operatively linked to a human placental alkaline phosphatase secretory signal sequence and a polyhedrin promoter, and (b) a chimeric gene encoding a portion of a VH region and a portion of an IgG1 heavy chain, both operatively linked to a honey bee melittin secretory signal sequence and a P10 promoter.

### Claim 53

A baculovirus expression vector comprising (a) a chimeric gene encoding a portion of a VL region and a portion of a gene encoding a κ light chain, both operatively linked to a human placental alkaline phosphatase secretory signal sequence and a polyhedrin promoter, and (b) a chimeric gene encoding a portion of a VH region and a portion of an IgG1 heavy chain, both operatively linked to a honey bee melittin secretory signal sequence and a P10 promoter.

### Claim 54

An expression vector comprising (a) a portion of a gene encoding a κ light chain constant region operatively linked to a human placental alkaline phosphatase secretory signal sequence and a polyhedrin promoter, and (b) a portion of a gene encoding an IgG, heavy chain constant region operatively linked to a honey bee melittin secretory signal sequence and a P10 promoter.

### Claim 55

An expression vector comprising (a) a portion of a gene encoding a λ light chain constant region operatively linked to a human placental alkaline phosphatase secretory signal sequence and a polyhedrin promoter, and (b) a portion of a gene encoding an IgG1 heavy chain constant region operatively linked to a honey bee melittin secretory signal sequence and a P10 promoter.

### Claim 56

A vector comprising the nucleic acid sequence as set forth in SEQ ID NO:6.

### Claim 57

A vector comprising the nucleic acid sequence as set forth in SEQ ID NO:7.

### Claim 58

A vector comprising the nucleic acid sequence as set forth in SEQ ID NO:89.

### Claim 59

A vector comprising the nucleic acid sequence as set forth in SEQ ID NO:90.

### Claim 60

A vector comprising the nucleic acid sequence as set forth in SEQ ID NO:91.
